This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort
The search for a "616 KB" article points directly to a significant medical study titled (616 KB)
The study highlighted a few differences between "real-world" patients and those in trials: This article, available through PubMed Central (PMC) ,
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics Key Findings and Statistics : Despite the high
: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials